InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by Alkon Daniel L., Directeur Scientifique. Officer active across 1 company, notably Synaptogenix, Inc.. Cumulatively, 6 filings have been logged. Breakdown: 2 buys · 1 sell. Total volume traded: €158k. History available since 14 June 2021. The latest transaction was disclosed on 16 December 2022 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations6 total
19,688 shares@ US$1.171913.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-22-128768:0
43,750 shares0Common Stock, par value $0.0001 per shareSEC:0001104659-22-123807:0
80,000 shares0Common Stock, par value $0.0001 per shareSEC:0001104659-21-092713
80,000 shares0Common Stock, par value $0.0001 per shareSEC:0001104659-21-092713:0
10,000 shares@ US$8.2643.1% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-21-081898
Ideal exit: 11 Mar 2022 (T+270)
10,000 shares@ US$8.2650.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-21-081898:0
Ideal exit: 11 Mar 2022 (T+270)
6 of 6 declarations
About Alkon Daniel L.
Daniel L. Alkon serves as Chief Scientific Officer at Synaptogenix, Inc. He is responsible for leading the company's scientific and research initiatives, contributing to innovation and the development of new treatments. His scientific expertise is crucial for Synaptogenix's success.
